Cargando…

Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose

GWN323, an agonistic human anti‐GITR (glucocorticoid‐induced TNFR‐related protein) IgG1 antibody, was studied clinically as an immuno‐oncology therapeutic agent. A model‐based minimum anticipated biological effect level (MABEL) approach integrating in vitro and in vivo data informed dose selection f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Yan, Knee, Deborah, Chen, Xinhui, Dang, Anhthu, Mataraza, Jennifer, Wolf, Babette, Sy, Sherwin K. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468570/ https://www.ncbi.nlm.nih.gov/pubmed/35731955 http://dx.doi.org/10.1111/cts.13355

Ejemplares similares

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

Dr. Elizabeth Mabel Henderson
Publicado: (1911)

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology
por: Ji, Yan, et al.
Publicado: (2018)

First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
por: Schaller, Teilo H, et al.
Publicado: (2020)

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR
por: Moody, Gordon, et al.
Publicado: (2015)

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
por: Chan, Sarah, et al.
Publicado: (2022)

Concepts for agonistic targeting of CD40 in immuno-oncology
por: Richards, David M., et al.
Publicado: (2019)

Quantitative systems pharmacology model of GITR‐mediated T cell dynamics in tumor microenvironment
por: Ji, Yan, et al.
Publicado: (2023)

Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol
por: Date, Kathryn, et al.
Publicado: (2023)

323P Oncology care in the Republic of Kazakhstan during COVID-19
por: Kaidarova, D., et al.
Publicado: (2020)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
por: Shrimali, Rajeev, et al.
Publicado: (2017)

Peptides GWN and GW protect kidney cells against Dasatinib induced mitochondrial injury in a SIRT1 dependent manner
por: Bhullar, Khushwant S., et al.
Publicado: (2021)

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
por: Tigue, Natalie J., et al.
Publicado: (2017)

Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
por: Narumi, Kenta, et al.
Publicado: (2019)

CD8(+) T Cells: GITR Matters
por: Ronchetti, Simona, et al.
Publicado: (2012)

Getting Lost in History: Mabel Purefoy FitzGerald and the Origins of Hydrochloric Acid in the Gastric Mucosa
por: Tissot van Patot, Martha C
Publicado: (2021)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Gateways not gatekeepers – reaching seldom-heard groups to gather public health community insights: Mabel Lie
por: Lie, M, et al.
Publicado: (2022)

Reviewers BJCVS 32.3
Publicado: (2017)

Poster Sessions 323-461
Publicado: (2002)

The Role of GITR/GITRL Interaction in Autoimmune Diseases
por: Tian, Jie, et al.
Publicado: (2020)

Targeting GITR in cancer immunotherapy – there is no perfect knowledge
por: Davar, Diwakar, et al.
Publicado: (2023)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Immuno-Oncology Essentials: An Overview
por: Hoffner, Brianna
Publicado: (2019)

Multiplex imaging in immuno-oncology
por: Zhao, Chen, et al.
Publicado: (2023)

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira, et al.
Publicado: (2015)

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira A., et al.
Publicado: (2016)

Medical negligence claims and the health and life satisfaction of Australian doctors: a prospective cohort analysis of the MABEL survey
por: Bradfield, Owen M, et al.
Publicado: (2022)

Building capacity for mental health resilience – local impact of the UK Better Mental Health Fund: Mabel Lie
por: Lie, M, et al.
Publicado: (2022)

Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology
por: Upadhyaya, Punit, et al.
Publicado: (2022)

5G for future wireless networks: second EAI international conference, 5GWN 2019, Changsha, China, February 23-24, 2019, proceedings
por: Leung, Victor C M, et al.
Publicado: (2019)

The Greek world, 479-323 BC
por: Hornblower, Simon
Publicado: (1991)

The role of GITR single‐positive cells in immune homeostasis
por: Nocentini, Giuseppe, et al.
Publicado: (2017)

New emerging targets in cancer immunotherapy: the role of GITR
por: Buzzatti, Giulia, et al.
Publicado: (2020)

482. The modern face of esophageal candidiasis (EC) in an oncology center: Analysis of 323 cancer patients with EC
por: Matsuo, Takahiro, et al.
Publicado: (2022)

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira A., et al.
Publicado: (2016)

Immunologically effective dose: a practical model for immuno-radiotherapy
por: Serre, Raphaël, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vgeu95038kuhdheljq8g1k88ig